12-Nitrolinoleate (12-Nitro-9-cis,12-cis-octadecadienoic acid) is an activator for peroxisome proliferator-activated receptor γ (PPARγ). 12-Nitrolinoleate is a nitrated form of linoleic acid. 12-Nitrolinoleate can be formed upon exposure to acidified nitrate and found in human red blood cells and plasma. 12-Nitrolinoleate can activate PPARγ-dependent gene expression in MCF-7 cells expressing PPARγ with an EC50 = 0.045 μM. 12-Nitrolinoleate is able to inhibit LPS-induced NF-κB transcription in RAW 264.7 cells. 12-Nitrolinoleate can inhibit IL-6, TNF-α and CCL2 induced by LPS.

MU1742-amide-C6-acid is a CK1δ/ε inhibitor. MU1742-amide-C6-acid can be used for synthesis of PROTAC AH081.

UNC10088 is a molecular glue targeting NSD2. UNC10088 mediates the formation of a stable ternary complex between SCFFBXO22 and the NSD2 PWWP1 domain. UNC10088 promotes ubiquitination of the SCFFBXO22-dependent NSD2 PWWP1 domain through reversible covalent bonding with the C326 region of FBXO22. UNC10088 could be used in cancer research.

DTS-201 (CPI-0004) is a peptidic prodrug of Doxorubicin). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer.

LCI765 is an orally active and selective PPARδ agonist, with an EC50 of 0.07 nM. LCI765 can be used for the research of diseases related to energy homeostasis such as metabolic syndrome.

NAA-004 is a novel azo compound formed by linking 5-aminosalicylic acid and 4-aminophenylacetic acid through an azo bond. NAA-004 has oral activity. NAA-004 can inhibit colon damage, intracavitary fluid accumulation, and MPO activity. NAA-004 can be used for research on colitis.

GLY-230 is an orally active compound. GLY-230 can inhibit nonenzymatic glycation and reduce glycated albumin. GLY-230 can reduce brain Aβ42 levels. GLY-230 can be used for the researches of metabolic and neurological disease, such as diabetic renal dysfunction.

SR 16234 (TAS-108) is a selective estrogen receptor modulator. SR 16234 is promising for research of pain symptoms associated with endometriosis.

PD 121981 is a angiotensin II receptor antagonist. PD 121981 can be used for the research of cardiovascular disease.

PDE4 ligand 2 is a CRBN E3 ligase ligand. PDE4 ligand 2 can be used to synthesize PROTAC such as PDE4 degrader-1. PDE4 ligand 2 can be studied in research for autoimmune and anti-inflammatory diseases.

KRP-105 is a potent, highly selective, and orally effective PPAR alpha (EC50 = 8 nM) agonist. KRP-105 can significantly reduce serum triglyceride, total cholesterol, and non high density lipoprotein cholesterol levels. KRP-105 can be used for research on metabolic diseases such as dyslipidemia.

4-[(1E)-2-Nitroethenyl]benzoic acid is an E3 ligase ligand. 4-[(1E)-2-Nitroethenyl]benzoic acid can be used for synthesis of PROTAC BRD4 Degrader-38.

VUF26034 (Compound 12b) is a photoresponsive ligand for the human β2-adrenergic receptor (β2-AR.

MC-02479 is a novel cephalosporin. RWJ-54428 has good activity against most of the organisms tested, including methicillin-resistant staphylococci, E. faecalis, and penicillin-resistant pneumococci, and has moderate activity against E. faecium.

CGP 31608 is a semisynthetic penem derivative with antibacterial activity. CGP 31608 is resistant to many important beta-lactamases (including the mutationally derepressed chromosomal enzymes). CGP 31608 can be used for the research of infection.

S-1255 is an orally active and highly selective endothelin ETA receptor antagonist (Kd=0.39 nM). S-1255 blocks vasoconstriction and sustains hypotensive effects in hypertensive rats. S-1255 is promising for research of hypertension and cardiovascular disorders.

BC-1175 (CB-181963) is a novel cephalosporin and antibacterial agent. CB-181963 displays strong binding to altered PBP 2a. CB-181963 demonstrates marked efficacy against MRSA, Klebsiella pneumoniae, Streptococcus pneumoniae, and Escherichia coli.

BAYV-3522 is an orally effective cephalosporin. BAYV-3522 has antibacterial activity against Gram positive bacteria and some respiratory pathogens. BAYV-3522 can be used in the research of infectious conditions.

HMRZ-62 is an antibacterial agent. HMRZ-62 exhibits antibacterial activity against Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus faecalis (VRE).

TGI-15 is a highly selective prostaglandin F receptor antagonist. TGI-15 inhibits downstream signaling pathways by blocking the binding of PGF2 α to FP receptors. TGI-15 can be used for research on fibrotic and inflammatory conditions.

BMT-136088 is a radioligand used for positron emission tomography (PET) imaging of idiopathic pulmonary fibrosis.

Sebrinoflast (Compound 5) is a NLRP3 inhibitor with an IC50 ≤1  μM for hNLRP3. Sebrinoflast can be used for inflammatory and cardiovascular diseases including NASH and atherosclerosis and neurological diseases like Alzheimer's disease research.

L-731128 is a novel alkyl citrate. L-731128 can be isolated as a minor component of Sporormiella intermedia (MF 5447, ATCC 20985) fermentations. L-731128 is a potent squalene synthase inhibitor, with an IC50 value of 767 nM.

Hepoxilin A3 methyl ester is the ester form of HxA3. Hepoxilin A3 methyl ester causes a receptor-induced rise in intracellular calcium through the release from intracellular stores in suspended human neutrophils.

AMG 7905 TFA is a hypothermia-inducing transient receptor potential vanilloid type 1 (TRPV1) antagonist. AMG 7905 TFA potentiates TRPV1 channels activation by protons and drives the reflectory inhibition of thermogenesis and tail-skin vasoconstriction, while potently blocking channel activation by capsaicin.

Psa-AR is a PROTAC degrader targeting PSMA. Psa-AR exhibits potent degradation ability of AR, AR-V7, and HSP90, and induces cell apoptosis. Psa-AR can be used for cancer research.

CGP 57698 is an efficient CysLT receptor (Ki = 5.7 nM) antagonist. CGP 57698 can effectively counteract bronchoconstriction caused by LTD4. CGP 57698 can be used for research on asthma or allergic conditions.

Butanixin (2-[(4-Butylphenyl)amino]-3-pyridinecarboxylic acid) is a cyclooxygenase (COX) inhibitor. It exerts anti-inflammatory and analgesic activity by reducing prostaglandin production. It is used in the research of musculoskeletal disorders.

idoBR1 is an orally active amino acid with an amino sugar. idoBR1 can significantly inhibit LPS induced TNF-α production and MAPK signaling pathway. idoBR1 can inhibit bacteria and human sialidase. idoBR1 can inhibit bacterial and human sialidase and reduce the binding of CD44 to hyaluronic acid (HA). idoBR1 can reduce the release of pro-inflammatory factors and promote the generation of anti-inflammatory factors. idoBR1 can be used for research on inflammatory conditions.

Gemigliptin (LC15-0444 ) tartrate hydrate is a selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate hydrate exhibits potent anti-glycation properties. Gemigliptin tartrate hydrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications.